MedTrace Logo

Trial of L-DOPA as a Treatment to Improve Vision in Albinism

NCT01176435 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2018-05-02

Study results available
· View outcomes & findings →

Summary

This project will evaluate the effect of two doses of levodopa (L-DOPA) in a randomized, placebo-controlled, double-masked clinical trial to see if vision can be improved in individuals with albinism. The hypothesis is that providing L-DOPA to the retinas of these individuals may increase melanin pigment production. Increased melanin has previously been shown to be associated with improved vision.

Conditions

  • Albinism

Interventions

DRUG

Levodopa

Solution taken orally three times a day.

DRUG

Levodopa

Solution taken orally three times a day.

DRUG

Placebo

Solution taken orally three times a day.

Sponsors & Collaborators

Principal Investigators

  • Gail Summers, M.D. · University of Minnesota

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
3 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01176435 on ClinicalTrials.gov